Sexual Health
VILITRA 60
CLASSIFICATION: ERECTILE DYSFUNCTION (PDE5 INHIBITOR)
ACTIVE SUBSTANCE: VARDENAFIL
FORM: 100 PILLS x 60 MG
ACTIVE HALF-LIFE: 4-5 HOURS
DOSAGE: MEN 10-20 MG/DAY
ACNE: NO
WATER RETENTION: NO
HBR: PERHAPS
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: CENTURION LABORATORIES
ACTIVE SUBSTANCE: VARDENAFIL
FORM: 100 PILLS x 60 MG
ACTIVE HALF-LIFE: 4-5 HOURS
DOSAGE: MEN 10-20 MG/DAY
ACNE: NO
WATER RETENTION: NO
HBR: PERHAPS
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: CENTURION LABORATORIES
$120.00
Shipping Location :
International
U.S. Domestic
Related Offers
Shipped International
Ajanta Pharma, India
CLASSIFICATION: ERECTILE DYSFUNCTION (PDE5 INHIBITOR)
ACTIVE SUBSTANCE: VARDENAFIL
FORM: 10 PILLS x 20 MG
ACTIVE HALF-LIFE: 4-5 HOURS
DOSAGE: MEN 10-20 MG/DAY
ACNE: NO
WATER RETENTION: NO
HBR: PERHAPS
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: AJANTA PHARMA
ACTIVE SUBSTANCE: VARDENAFIL
FORM: 10 PILLS x 20 MG
ACTIVE HALF-LIFE: 4-5 HOURS
DOSAGE: MEN 10-20 MG/DAY
ACNE: NO
WATER RETENTION: NO
HBR: PERHAPS
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: AJANTA PHARMA
$35.00
Shipped International
Centurion Laboratories
CLASSIFICATION: ERECTILE DYSFUNCTION (PDE5 INHIBITOR)
ACTIVE SUBSTANCE: VARDENAFIL
FORM: 100 PILLS x 20 MG
ACTIVE HALF-LIFE: 4-5 HOURS
DOSAGE: MEN 10-20 MG/DAY
ACNE: NO
WATER RETENTION: NO
HBR: PERHAPS
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: CENTURION LABORATORIES
ACTIVE SUBSTANCE: VARDENAFIL
FORM: 100 PILLS x 20 MG
ACTIVE HALF-LIFE: 4-5 HOURS
DOSAGE: MEN 10-20 MG/DAY
ACNE: NO
WATER RETENTION: NO
HBR: PERHAPS
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: CENTURION LABORATORIES
$99.00
Shipped USA Domestic
Dragon Pharma, Europe
Product Details Dragon Pharma
Active Substance Vardenafil Phosphodiesterase type 5 inhibitor
Strength 20 mg/tablet
Package 100 tablets 2,000 mg total labeled content
Form Oral tablets
Estimated Half-Life Approximately 4–5 hours
Drug Class PDE5 inhibitor
Mechanism PDE5 inhibition
Primary Concerns Blood pressure and cardiovascular effects
$240.00
Shipped International
Centurion Laboratories
CLASSIFICATION: ERECTILE DYSFUNCTION (PDE5 INHIBITOR)
ACTIVE SUBSTANCE: VARDENAFIL
FORM: 100 PILLS x 10 MG
ACTIVE HALF-LIFE: 4-5 HOURS
DOSAGE: MEN 10-20 MG/DAY
ACNE: NO
WATER RETENTION: NO
HBR: PERHAPS
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: CENTURION LABORATORIES
ACTIVE SUBSTANCE: VARDENAFIL
FORM: 100 PILLS x 10 MG
ACTIVE HALF-LIFE: 4-5 HOURS
DOSAGE: MEN 10-20 MG/DAY
ACNE: NO
WATER RETENTION: NO
HBR: PERHAPS
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: CENTURION LABORATORIES
$95.00
Shipped International
Bayer Schering, Turkey
CLASSIFICATION: ERECTILE DYSFUNCTION (PDE5 INHIBITOR)
ACTIVE SUBSTANCE: VARDENAFIL
FORM: 4 PILLS x 10 MG
ACTIVE HALF-LIFE: 4-5 HOURS
DOSAGE: MEN 10-20 MG/DAY
ACNE: NO
WATER RETENTION: NO
HBR: PERHAPS
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: BAYER SCHERING
$62.00
Shipped International
Centurion Laboratories
CLASSIFICATION: ERECTILE DYSFUNCTION (PDE5 INHIBITOR)
ACTIVE SUBSTANCE: VARDENAFIL
FORM: 100 PILLS x 40 MG
ACTIVE HALF-LIFE: 4-5 HOURS
DOSAGE: MEN 10-20 MG/DAY
ACNE: NO
WATER RETENTION: NO
HBR: PERHAPS
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: CENTURION LABORATORIES
ACTIVE SUBSTANCE: VARDENAFIL
FORM: 100 PILLS x 40 MG
ACTIVE HALF-LIFE: 4-5 HOURS
DOSAGE: MEN 10-20 MG/DAY
ACNE: NO
WATER RETENTION: NO
HBR: PERHAPS
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: CENTURION LABORATORIES
$115.00
Kalpa Pharmaceuticals LTD, India
Product Details Kalpa Pharmaceuticals
Active Substance Tadalafil Also known as Cialis
Strength 20 mg/tablet
Package 20 or 100 tablets 400 or 2,000 mg total labeled content
Form Oral tablets
Drug Class PDE5 inhibitor
Terminal Half-Life ~17.5 hours
Primary Target PDE5
Metabolism Primarily CYP3A4
Kalpa Pharmaceuticals LTD, India
Product Details Kalpa Pharmaceuticals
Active Substance Sildenafil Citrate Equivalent to sildenafil
Strength 100 mg/tablet
Package 20 or 100 tablets 2,000 or 10,000 mg labeled strength
Form Oral tablets
Drug Class PDE5 inhibitor
Terminal Half-Life ~4 hours
Primary Target PDE5
Metabolism Primarily CYP3A4